Panelists discuss how recent FDA approvals and SC amivantamab data support broader use of subcutaneous therapy in NSCLC.
Panelists discuss how SC delivery enhances patient convenience and health care efficiency in NSCLC treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback